January 10, 2025 07:00 AM ESTUpdated 08:07 AM
Peer Review

John Maraganore turns to ex-Al­ny­lam col­league to lead his lat­est RNAi bet; Amy­lyx names com­mer­cial chief

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Max Bayer

Pharma Reporter

→ City Ther­a­peu­tics broke cov­er in Oc­to­ber with a $135 mil­lion Se­ries A and the op­por­tu­ni­ty for ex­ec­u­tive chair­man John Maraganore to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

Four biotechs emerge with $800M and in-li­censed as­sets on Fri­day

In­tel­lia to cut work­force by 27%, plans com­mer­cial­iza­tion of first CRISPR ther­a­py in 2027

Lil­ly ven­tures in­to pul­monary fi­bro­sis with start­up Me­di­ar

With $120M, GSK-al­lied Ouro Med­i­cines throws its hat in­to bur­geon­ing TCE ring

A service from the Financial Times